Taxing times ahead for Ranbaxy-Daiichi deal?
The pharmaceutical poster boy Malvinder Mohan Singh, who will continue as CEO and managing director of the entity, has not only attracted media attention with his billion dollar Daiichi deal, but he has also invited attention from the taxman as well. NDTV has learnt from the income tax department sources that the IT department will examine the Ranbaxy deal to examine if capital gains tax should be levied.
